The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

• Status: Recruiting
• Trial end date: 2025-06-01

Summary

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

• Phase: Phase 3

Details

• Lead Sponsor: Inozyme Pharma